Editor-in-Chief & Deputy Editor 2019-2021





Deputy Editor:



Sponsors & Partners

Acta Gastroenterologica Belgica is supported by grants from its major sponsors


Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma







Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies









The liver involvement of the hydatid disease : a systematic review designed for the hepato-gastroenterologist

Price: €10,00

Hydatidosis is not uncommon in Western Europe, mainly due to the presence of immigrants from endemic countries, and hepatogastroenterologist must then be able to manage this infectious disease. The hepatic hydatidosis is due to development in the liver of the larvae of Echinococcus granulosus that causes liver cysts. It can grow in size throughout the years and can give rise to complications, mainly pain, super-infection or cyst rupture. Recent progresses in imaging modalities play an important role in diagnosis, classification and evaluation of response to treatment of the cysts. Imaging techniques led to both Gharbi’s and WHO’s classifications. Those can provide markers of cyst activity and can help to determine the best therapeutic strategy. By combining two immunodiagnostic techniques, the diagnostic accuracy of laboratory tests is excellent. During the last decade, treatment has improved : the main therapeutic modality in the past was surgery, until the discovery of PAIR procedure (Puncture, Aspiration, Injection, Re- aspiration). Albendazole also plays an important role in the treatment of hydatid cysts either alone or as a pre-procedure or post procedure prophylaxis. This review will cover the major aspects of the disease emphasizing the recent diagnostic and therapeutic advances. (Acta gastroenterol. belg., 2013, 76, 210-218). [Product Details...]

Treatment of non-alcoholic fatty liver disease : Can we already face the epidemic ?

Price: €10,00

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder in the Western world. It comprises a disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which may progress to fibrosis, cirrhosis and its complications like hepatocellular carcinoma and liver failure. In addition, evidence is accumulating that NAFLD is an independent risk factor for cardiovascular diseases. Progress has been made in unraveling the pathogenesis, which paved the way for several clinical trials for the treatment of NAFLD. Life style intervention consisting of increased physical activity and dietary modifications, remain the cornerstone of the treatment. Some pharmacological agents show promising results, although on the basis of recent clinical trials no firm conclusions can be drawn. Suggestions for treatment in some particular groups of patients can be made. Further research is required to face the burden of NAFLD, which is already present in epidemic proportions. (Acta gastroenterol. belg., 2013, 76, 200-209). [Product Details...]

  • «« Start
  • « Prev
  • 1
  • Next »
  • End »»
Results 1 - 2 of 2